Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (May 2020)

41 slides from Windtree Therapeutics's investor presentation, May 7, 2020

  1. Slide 1: Windtree Therapeutics Corporate Presentation

    Windtree Therapeutics Corporate Presentation May 2020 OTCQB: WINT THERAPEUTICS WINDTREE

  2. Slide 2: Forward-looking Statements

    @ EQ WINDTREE Forward-looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements abo

  3. Slide 3: Risk Factors

    Risk Factors Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in our SEC filings. If any of the following risks actually occurs, our business, financial condition, resu

  4. Slide 4: Windtree Therapeutics

    Windtree Therapeutics Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company with multiple advanced cl FDA Fast Track Designation Potential for Breakthrough designation FDA, EMA Orphan Drug for RDS FDA Fast Track Designation, Orphan Drug S@ winptr we ‘al programs span

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones = Three clinical programs focused on significant markets with unmet needs = Multiple clinical and business milestones which have the potential to be catalysts 2020 2021 | Qi Q2 Q3 Q4 Ql Q2 Q3 Q4 Istaroxime Data, Early Cardiogenic Shock Study fas - Data,

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure and .. Early Cardiogenic Shock

  7. Slide 7: Heart Failure

    Heart Failure - The prevalence of HF is high and on the rise (as is mortality) # of Patients: 6M (U.S.) | 18M (Worldwide) Hospital Admissions: #1 cause of hospitalization in patients> 65 years old (U.S.) > 1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) Inpatient Mortality: Up to 7%

  8. Slide 8: Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need

    Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = There has not been meaningful new pharmacologic advancements in acute heart failure for decades = Current approaches to acutely improve cardiac function are associated with unwanted effects: Heart rhythm distur

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart. Dual Mechanism of At Inhibition of the sodium- e Stimulation of SERCA2a activity enhances potassium pump and effects on m calcium reuptake resulting in th

  10. Slide 10: Istaroxime AHF Phase 2b Study - Summary

    Istaroxime AHF Phase 2b Study - Summary Primary = Change in E/e’ at 24 hours (non-invasive estimate of PCWP) measured by Endpoint: echocardiography Trial Design: = Adult patients hospitalized for recurrent AHF (dyspnea plus need for IV furosemide 2 40mg) = 120 patients = Multicenter, double blind, p

  11. Slide 11: Primary Endpoint — Significant Changes in E/e' Ratio and Stroke Volume

    Primary Endpoint — Significant Changes in E/e' Ratio and Stoke Volume istaroxime 0.5 g/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo 20 20 10 10 00 co a0 40 ° £20 3 230 > e390 3 Efe’ 3, 50 50 Infusion period 3 infu - : < 60 as £0 pralues <0.034 70 20 Beene Ghours —28hous —ABhours eeeine how

  12. Slide 12: Systolic Blood Pressure Maintained or Increased During Treatment

    Systolic Blood Pressure Maintained or Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 g/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo 2 9 = ° E a ae Ea = 2 E3 5 SBP 5 : Se 53 ait | | |} ff 6 Infusion period oe ee ge ge * =0.011, ** FF FF oF oF OS * value =0.0

  13. Slide 13: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Create a strong phase 3 and partnership position - * Execute an additional study that is expected to complete Phase 2 and inform Phase 3 - 300 patients, 75 centers globally (estimates) * Leverage characteristics in a target population that most

  14. Slide 14: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output No Satisfactory Pharmacologic

  15. Slide 15: Istaroxime SBP Change from Baseline: Phase 2a and 2b Dose Groups

    Istaroxime SBP Change from Baseline to 6 or 24 Hours from the Phase 2a and 2b Dose Groups Istaroxime has the potential to improve blood pressure and organ perfusion in patients with AHF 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change 0.5 pg/kg/min 1.0 pg/kg/min

  16. Slide 16: Istaroxime — Early Cardiogenic Shock — Next Steps

    Istaroxime — Early Cardiogenic Shock — Next Steps + Initiate a study in early cardiogenic shock while we are preparing for the larger phase 2b acute heart failure study - ~60 patients conducted in the Europe and US - Start mid-2020 with data expected in Q2 2021 + Phase 2 clinical program suggests a

  17. Slide 17: COVID-19 Lung Injury Treatment

    COVID-19 Lung Injury Treatment Synthetic KL4 Surfactant for the Treatment of Lung Injury in COVID-19 Patients

  18. Slide 18: COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function

    COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function Uses angiosten- ACE2is a surface molecule on Damaged Type 2 cells Increased likelihood of converting enzyme 2 alveolar Type 2 cells of lungs, results in impaired mechanical ventilation (ACE2) for entry into the

  19. Slide 19: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 surfactant tre

  20. Slide 20: Surfactant Administration In Severe COVID-19 Lung Injury

    Surfactant Administration In Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = We believe our synthetic KL4 surfactant may have the potential to replace surfactant deficiency and resist the Si widespread surfactant destruction that can occur as a aA result of COVID-19

  21. Slide 21: Phase 2 Clinical Proposal: Lucinactant for COVID-19

    Phase 2 Clinical Proposal: Lucinactant (KL, Surfactant) For The Treatment of COVID-19 Initial phase 2 study will be to demonstrate changes in physiological parameters in COVID-19 associated lung injury and ARDS ¢ Up to 30 patients from 4-5 US sites (lead by institutions in Boston & Durham, NC) © Dos

  22. Slide 22: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19— Demonstrated Utility Across Various Respiratory Distress Extensive Studies in * 13 studies for intratracheal administration including RDS, BPD, acute Acute Lung Conditions: hypoxemic respiratory failure and adults with ARDS = 2,148 patients e

  23. Slide 23: AEROSURF®

    AEROSURF® Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS

  24. Slide 24: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and gas exchange = Physicians have to choose between invasive surfactant de

  25. Slide 25: AEROSURF® - Potential to Impact the Clinical Course of RDS

    AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Study results across each Parameters of these important parameters show evidence of a potential impact on the clinical cours

  26. Slide 26: Mitigating Risks and Strengthening Our Approach

    Mitigating Risks and Strengthening Our Approach Program Evolution Completed Three Phase 2a and 2b Trials = = Execute a small (n=~80 - 90) Bridging Study to transition to EOP2 / Phase 3 Efficacy in reducing nCPAP failure and the need for intubation = = Demonstrate the new ADS works and supplement pha

  27. Slide 27: Summary

    Summary

  28. Slide 28: Financial Snapshot & Capitalization

    Financial Snapshot & Capitalization = Cash & Equivalents: $22.6M (as of 12/31/19) = Debt: $4.6M bank credit facility currently due in March 2022 * Guaranteed by Lee’s Pharmaceutical Holdings Ltd. (SEHK:950) Securities Common Equivalents | Common Stock Ownership (12/31/19) __‘# of Shares % Common Sto

  29. Slide 29: Multiple Development and Business Activities Create a Robust Outlook of Potential Milestones

    Multiple Development and Business Activities Create a Robust Outlook of Potential Milestones Strategy for Value Creation Planned Milestones * Three clinical programs focused on significant markets with unmet needs = Multiple dinical and business milestones which have the potential to be catalysts 20

  30. Slide 30: Windtree Therapeutics

    Windtree Therapeutics “Striving to deliver Hope for a Lifetime!” we GS winDTtREE

  31. Slide 31: Appendix

    Appendix Se wINDTREE we" .

  32. Slide 32: In-Hospital Mortality, %

    In-Hospital Mortality, % Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF Patients and Their Outcomes In-Hospital Mortality Rates by Admission Systolic Blood Pressure Deciles (n = 48,567) I [50-104 105-114] 115-123 124-191 192-199 140-147 148-156 167-168 169-188

  33. Slide 33: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: ° LVEF < 35% © SBP 90-150 mmHg =

  34. Slide 34: Istaroxime Phase 2b Study - Holter Monitoring

    Istaroxime Phase 2b Study Favorable Profile Observed with 24-hour Holter Monitoring Clinically significant arrhythmias Clinically significant arrhythmias 120% —105% 105% 105% siceae 10.0% 200% 200% 20.0% 8.0% 6.0% 50% 0.0% 10.0% 40% 2.4% 2.4% ae ON | i 20% 5.0% on oo Baseline Day! (infusion) Baselin

  35. Slide 35: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events istaroxime 0.5 istaroxime 1.0 Pooled placebo : e pes) me/Ke/min me/Ke/min (n=41) (n=40) Alladverse events 23 (59.0%) 31 (75.6%) 33 (82.5%) Adverse events leading to discontinuation 1 (2.6%) - 4 (20.0%) Serious adverse events 2 (5.1%) 2 (4.9%) 6 (15.0%) Cardiac deat

  36. Slide 36: Pre-Clinical Programs

    Pre-Clinical Programs Novel Oral SERCA2a Activators for HF + Acute Pulmonary Platform The Company also has early exploratory research programs to identify potential product candidates including: Cardiovascular Selective SERCA2a Dual Mechanism Compounds Activators for Heart Failure * Oral &i.v. thera

  37. Slide 37: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf

  38. Slide 38: Windtree Technology Platform - AEROSURF®

    Windtree Technology Platform - AEROSURF® Proprietary Synthetic KL4 Surfactant + Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ability to aerosolize KLa surfactant for RDS approved by the FDA Lyo

  39. Slide 39: Transformative Potential of AEROSURF®

    Transformative Potential of AEROSURF® RISKS Surfactant Therapy respiration Surfactant therapy delivers near-immediate clinical improvement Reversing surfactant deficientey.has /a profound positive impact on \ BPD Infection, ventilator-induced pneumonia nCPAP Respiratory Support “Avoids exposure to t

  40. Slide 40: References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury

    References Supporting Utilization of KL, Surfactant for the Treatment of Lung Injury Hoffmann, MH. Kleine Weber, etal. (2020). "The novel coronavirus 2019 (2019-nCoV) uses the SARS-corcnavirus receptor ACE2 andthe cellular protease TMPRSS2 for entry into target cellsi0.1101/2020.01.31.929042." bioRk

  41. Slide 41: Surfactant in ARDS References

    Surfactant in ARDS References 1. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore Wi, et al. Bovine surfactant therapy for patients with acute respiratory distresssyndrome.Am J Respir Crit Care Med. 1997;155:1309-1315. 2. Wiedemann H, Baughman R, de BoisblancE,et al.,A multi centered

Windtree Therapeutics — Investor Presentation (May 2020) on 6ix